Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 May 1;26(5):1581-1589.
doi: 10.31557/APJCP.2025.26.5.1581.

Comparative Study of ERK1/2, Bcl2, and Sorcin with Clinicopathological Characteristics of Gastric carcinoma: Tubular Adenocarcinoma Vs Signet Ring Cell Carcinoma

Sushmita Ghosh  1   2 , Jayanta Chakrabarti  3 , Partha Nath  3 , Raya Banerjee  4 , Neyaz Alam  3 , Vilas D Nasare  1
Affiliations
Comparative Study

Comparative Study of ERK1/2, Bcl2, and Sorcin with Clinicopathological Characteristics of Gastric carcinoma: Tubular Adenocarcinoma Vs Signet Ring Cell Carcinoma

Sushmita Ghosh et al. Asian Pac J Cancer Prev. .

Abstract

Background and objective: Altered expression of tissue-specific tumor markers is associated with clinicopathological factors and poor clinical outcomes in Gastric Cancer (GC). However, the markers have been scarcely explored in the context of the distinct GC subtypes, which are crucial for assessing treatment response. This study explores the nuanced differences between gastric tubular adenocarcinoma (TA) and signet ring cell carcinoma (SRCC), focusing on the correlation of ERK1/2, Bcl2, and Sorcin expression. The aim is to identify potential differences between the subtypes and assess the prognostic value of the markers in relation to clinicopathological outcomes.

Methods: Immunohistochemistry evaluated the ERK1/2, Bcl2 and Sorcin expression in 78 patients (TA=37, SRCC=33; other=8) diagnosed with advanced non-metastatic GC. Descriptive statistics and correlations were assessed between the proteins and clinicopathological features. Overall survival and hazard risk (HR) were determined using Kaplan-Meier and Cox proportional hazard analyses.

Results: Higher ERK1/2 (66%) and lower Bcl2 (51%) expression was demonstrated in SRCC, whereas the opposite trend was noted in TA cases. On the contrary, Sorcin expression was high in both, however, predominant in SRCC (66%). Notably, post-NACT, the expression of these proteins was elevated. Significant difference in survival between TA (22±3.03 months) and SRCC (12±1.62 months) (p=0.007) was observed. In SRCC, higher ERK1/2, Sorcin, and low Bcl2 expressions were associated with shorter survival with HR>1 (p<0.05). Significant correlation between Sorcin and clinicopathological factors was analysed both in TA and SRCC (p<0.001) compared to ERK1/2 and Bcl2 expression. Sorcin expression was further associate with treatment response in non-responders (post-NACT) in both TA and SRCC (p<0.05).

Conclusion: High ERK1/2, Sorcin, and low Bcl2 expression prevailed in SRCC cases. These expressions were upregulated post-NACT in both subtypes. SRCC patients had shorter OS, moreover expression of ERK1/2, Sorcin, and Bcl2 correlated with poor survival outcomes and major clinicopathological factors in SRCC cases.

Keywords: Chemotherapy; Gastric cancer; Hazard ratio; Overall survival; Upfront Surgery.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Figures

Figure 1
Figure 1
Flowchart Representing Study Design of Advanced Gastric Cancer Patients
Figure 2
Figure 2
Haematoxylin and Eosin Staining of A. Tubular Adenocarcinoma (40X and 100X) B. Signet Ring Cell Carcinoma (40X and 100X). Immunostaining of ERK1/2, Bcl2 and Sorcin in C. Tubular Adenocarcinoma, 100X (Left), Graph representing the number of patients with Tubular Adenocarcinoma exhibiting ERK1/2, Bcl2 and Sorcin expression (Right) D. Signet Ring Cell Carcinoma (Left), Graph representing the number of patients with Signet Ring Cell Carcinoma exhibiting ERK1/2, Bcl2 and Sorcin expression (Right)
Figure 3
Figure 3
Kaplan-Meier and Cox-Proportional Analysis of A. Tubular Adenocarcinoma and Signet Ring Cell Carcinoma B. ERK1/2, Bcl2 and Sorcin in Tubular Adenocarcinoma C. ERK1/2, Bcl2 and Sorcin in Signet Ring Cell Carcinoma
Figure 4
Figure 4
The Heatmap Representing the Relationship between ERK1/2, Bcl2 and Sorcin Expression and Clinicopathological Factors in A. Tubular Adenocarcinoma (TA) and B. Signet Ring Cell carcinoma (SRCC)
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. - PubMed
    1. Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3(3):251–61. - PMC - PubMed
    1. Saitoh T, Takamura A, Watanabe G. Endoscopic and clinicopathological features of intramucosal, histologically mixed-type, low-grade, well-differentiated gastric tubular adenocarcinoma with the potential for late-onset lymph node metastasis. BMC Gastroenterol. 2018;18(1):189 . - PMC - PubMed
    1. Li Y, Zhu Z, Ma F, Xue L, Tian Y. Gastric signet ring cell carcinoma: Current management and future challenges. Cancer Manag Res. 2020;12:7973–81. - PMC - PubMed
    1. Cravo M, Fidalgo C, Garrido R, Rodrigues T, Luz G, Palmela C, et al. Towards curative therapy in gastric cancer: Faraway, so close! World J Gastroenterol. 2015;21(41):11609–20. - PMC - PubMed

Publication types

MeSH terms